Kolon TissueGene has taken a significant step forward by expanding the potential use of its flagship drug, TG-C, from knee osteoarthritis to spinal disease.
The company recently announced it has secured patents in the United States and Australia for using TG-C to treat degenerative disc disease (DDD), a common cause of back pain. It also set a clear timeline, aiming to administer the first dose in a U.S. Phase 1 clinical trial by December 2026. This move signals a clear strategy to evolve TG-C from a single-indication treatment into a broader platform technology.
This development doesn't exist in a vacuum; its timing is critical. It comes just ahead of the highly anticipated top-line results from the U.S. Phase 3 trial for TG-C in knee osteoarthritis, expected in July. This creates a powerful causal link. First, a positive outcome in the knee trial would not only pave the way for commercialization for that indication but also significantly de-risk and boost confidence in the spine program, as both treatments use the same core technology. Conversely, a disappointing result would cast a serious shadow over the entire platform's viability.
Looking back, this expansion has been methodically built. The journey began with a crucial regulatory milestone: in December 2023, the U.S. FDA approved the company's Investigational New Drug (IND) application, giving the green light to start human trials for the spine indication. Second, Kolon TissueGene has been constructing an intellectual property 'fortress' around TG-C. This includes earlier patents for the drug's composition in Europe and Australia, now strengthened by these new indication-specific patents. This robust IP portfolio makes the asset more attractive for potential licensing or partnership deals, even with early-stage data.
Furthermore, the company has secured the necessary resources to execute these plans. In September 2025, it raised KRW 122.5 billion (approx. $90 million) through convertible bonds, and in March 2026, it signaled the recommissioning of its manufacturing facilities. These actions demonstrate financial and operational readiness, addressing potential concerns about its ability to manage large-scale trials and eventual commercial production. All these steps are part of a broader effort to rebuild trust following the 2019 revocation of the drug's approval in South Korea, making progress under the FDA's stringent oversight paramount.
- Pipeline: A collection of products a company has in development, ranging from early research to late-stage clinical trials.
- Investigational New Drug (IND): An application submitted to a country's regulatory body (like the U.S. FDA) to get permission to start clinical trials of a new drug in humans.
- Top-line Results: The initial, high-level summary of the main outcomes from a clinical trial, released before the full, detailed data is published.